Mucinex NDA pipeline
This article was originally published in The Tan Sheet
Executive Summary
Adams Labs will submit NDAs in 2003 for respiratory products combining guaifenesin with pseudoephedrine and guaifenesin with dextromethorphan, firm says Jan. 21. Adams receives same-day FDA approval for 1,200 mg guaifenesin tablets (NDA 21-282/S-001), which will join 600 mg dose in March with similar behind-the-counter sales strategy. Mucinex 1,200 mg offers convenient dosing regimen of one tablet twice a day and is indicated to "help loosen phlegm" and "make coughs more productive." A 20-count bottle will retail for roughly $15, Adams says. Like Mucinex 600 mg, the higher dose will be promoted to physicians, pharmacists (1"The Tan Sheet" July 22, 2002, p. 3)...
You may also be interested in...
Adams Labs Mucinex Marketing Strategy Targeting Healthcare Professionals
Adams Laboratories plans to launch Mucinex "long-acting" guaifenesin tablets with a behind-the-counter sales strategy
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.